A Phase 1 interventional study of Artificial sweeteners; Carbohydrate Sugars and Water in Healthy, sponsored by University Hospital, Basel, Switzerland. Completed. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-09-17.
Sponsored by University Hospital, Basel, Switzerland · Phase 1, Interventional, and Basic science
The purpose of this study is to examine the influence of artificial sweeteners (aspartame, acesulfame K, sucralose) and carbohydrate sugars (glucose, fructose) on the release of gastrointestinal satiety hormones in humans.
Artificial Sweeteners significantly lower energy density of foods and beverages. They are used by diabetics as sugar substitutes as well as by consumers as aids for dietary control. Despite numerous studies which show mainly no influence of artificial sweeteners on glucose metabolism and food intake, discrepancies consist about the real effects of artificial sweeteners. Studies by Blundell and Hill in 1986 have however shown that the consumption of artificial sweeteners resulted in an increase of appetite ratings; the efficiency of AS has therefore been questioned. With respect to the world wide increase in the prevalence in obesity, it seems important to clarify whether artificial sweeteners can help regulate body weight or not. This study will explore the effect of artificial sweeteners on the release of the gastrointestinal satiety hormones PYY, GLP-1, GIP and ghrelin.
University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
Dietary Supplement: Water
sweetening agent dissolved in tap water, administered via intragastric tube
Gastrointestinal peptide secretion
Time frame: 2 hour blood sampling
No study locations are listed for this record.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland